Corrigendum: Soluble PD−L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis
Main Authors: | Takashi Shimizu, Eisuke Inoue, Ryotaro Ohkuma, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-12-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1345513/full |
Similar Items
-
Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis
by: Takashi Shimizu, et al.
Published: (2023-11-01) -
Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies
by: Ryotaro Ohkuma, et al.
Published: (2021-12-01) -
The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study
by: Takashi Kurosaki, et al.
Published: (2023-12-01) -
Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors
by: Ryotaro Ohkuma, et al.
Published: (2023-09-01) -
Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma
by: Heli Vajavaara, et al.
Published: (2021-01-01)